Online Program Home
My Program

Abstract Details

Activity Number: 336 - Surrogate Endpoints: Bridging the Roles of Biology and Statistics for Clinical Outcome Prediction
Type: Topic Contributed
Date/Time: Tuesday, July 31, 2018 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract #329153 Presentation
Title: Assessment of Biomarkers and Surrogate Endpoints in Drug Development
Author(s): Ivan Chan* and Shu-Chih Su
Companies: AbbVie Inc and Merck Research Labs
Keywords: biomarker; surrogate endpoint; drug development

In modern drug development, identification of biomarkers and surrogate endpoints is becoming more important in many aspects of research and development. Predictive biomarkers can help accelerate development of a new drug for precision medicine by identifying subgroups of patients that will benefit more of the new treatment. Surrogate endpoints are intermediate endpoints (often based on biomarkers) that are highly predictive of clinical outcomes. They can be used in lieu of clinical outcome variables to measure the efficacy of a new treatment in clinical trials, in an effort to expedite the development of the new treatment. In this presentation, we will discuss the statistical methods and challenges in assessing biomarkers and surrogate endpoints from the industry perspective. Real examples will be used to illustrate the points. In particular, we will discuss a case study of the evaluation of surrogate endpoint for a herpes zoster vaccine using both of the Prentice criteria and causal inference framework.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program